Marijuana Reclassified To Schedule III

Key Takeaways

• AG Blanche reclassifies medical marijuana to Schedule III on April 24, 2026
• DEA hearing on full rescheduling starts June 29, 2026, replacing 2024 proceedings
• Village Farms to activate U.S. cultivation once regulations allow
• Federal enforcement against illicit trafficking remains unchanged under new schedule
• Schedule III status eases research, banking, and tax constraints for cannabis firms

Pulse Analysis

The Justice Department’s swift reclassification of medical cannabis to Schedule III marks the most significant federal policy shift in the sector since the 1970s. By aligning the Controlled Substances Act with President Trump’s 2025 executive order, the administration aims to harmonize federal law with the patchwork of state medical programs. This move also satisfies international treaty obligations under the Single Convention on Narcotic Drugs, signaling a broader willingness to integrate cannabis into mainstream medical practice while retaining strict controls on illicit distribution.

For the industry, the Schedule III designation removes a long‑standing impediment to research funding, banking services, and tax treatment. Companies can now seek traditional financing and benefit from Section 280E relief, which previously penalized cannabis businesses with higher tax rates. Village Farms International, one of the world’s largest cannabinoid cultivators, announced plans to bring its U.S. farms online as soon as state and federal permits align, positioning itself to capture a surge in demand for regulated medical products. Investors are likely to reassess valuations, given the reduced regulatory risk and expanded market access.

The upcoming DEA hearing on June 29, 2026 will determine whether the Schedule III status extends to all marijuana products, potentially moving the plant from Schedule I to a less restrictive tier. A favorable outcome could unlock a wave of clinical trials, spur pharmaceutical partnerships, and further normalize cannabis in healthcare. However, the administration has emphasized that enforcement against illegal trafficking will continue, underscoring a balanced approach that seeks to protect public health while fostering a legitimate medical market.